Nascent Biotech, Inc.
NBIO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.44K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $34,443.00 |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 1.63 |
| Outstanding Shares | 172,202,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.02 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Nascent Biotech, Inc.
2 employees
CEO: Sean Carrick
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address a...